Navigation Links
Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury

SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN)( and Entest BioMedical Inc., its wholly owned subsidiary, announced today they have jointly submitted a Project Summary Report to the U.S. Army Medical Research and Materiel Command (USAMRMC) for consideration of funding to study the therapeutic potential of adipose-derived stem cells (ASCs) harvested from liposuction for treating Traumatic Brain Injury (TBI). The USAMRMC provides solutions to medical problems of importance to the American warfighter at home and abroad. BMSN is a San Diego-based biotechnology research and development company. Entest BioMedical Inc. is focused on research & development in regenerative medicine.

Currently, there are no effective therapeutic approaches to reverse the injury. Combat-related brain injuries in service members returning from the ongoing conflicts in Iraq and Afghanistan appear to be higher than in previous conflicts. Walter Reed Army Medical Center has stated that nearly 30% of all patients with combat-related injuries have sustained a TBI mostly from roadside bombs and other explosives.

The BMSN-Entest BioMedical Project Summary Report for review and funding, entitled "An Adipose-derived Stem Cell Therapy for Traumatic Brain Injury," is authored by Feng Lin, M.D., Ph.D., BMSN's Laboratory/Scientific Director. He has extensive experience with tissue imaging, cell and molecular biology, animal model work, among other expertise areas. Dr. Lin is serving as the Chief Investigator for Entest BioMedical Inc.

"The objective of our proposal is to develop an effective ASC-based therapy for TBI," said David Koos, Chairman and CEO of BMSN. Adipose, or fat, tissue is the most abundant and accessible source of adult stem cells that can be easily harvested from liposuction, and can also differentiate into neural cells, he noted.

"Specifically, we will substantially study the therapeutic effect of ASCs on TBI-associated brain ischemia and inflammation via intravenous administration or by intro-cerebral transplantation. It is plausible that our proposed study will pave the way for an ASC-based therapy for TBI, which hopefully will be much more feasible and safer than other stem cell-based approaches," said Koos.

About Bio-Matrix Scientific Group

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a biotech research and development company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, asceptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

About Entest BioMedical Inc.:

Entest BioMedical Inc. is a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Matrix Scientific Group Announces New Hires to Management Team
2. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on
3. Bio-Matrix Scientific Group, Inc. Highlighted in Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
4. Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
5. Bio-Matrix Scientific Group CEO Tells Wall Street Transcript That Positive Cash Flow Is Possible in 09; New Stem Cell Banking Facility Is Growth Vehicle Over the Next Two Years, Says CEO in Exclusive News Interview
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. Bio-Matrix Scientific Group, Inc. Announces Preferred Stock Dividend and Spinoff of Wholly-Owned Subsidiary, Entest Biomedical, Inc.
8. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
9. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
10. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
11. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
Breaking Biology News(10 mins):